Skip to content

An experiment involving people with Rheumatoid arthritis (joint pain illness) to see the changes of illness level, involuntary action of heart and blood test to measure immune (protective) response by giving yoga

Effect of yoga therapy on disease activity, cardiac autonomic functions and inflammatory markers in patients of Rheumatoid arthritis - A randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/07/009132
Enrollment
150
Registered
2017-07-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients of Rheumatoid arthritis

Interventions

Intervention1: yoga therapy: Study group will undergo yoga therapy for 12 weeks (30 minutes, 3 times/week). Yoga therapy will be administered in the Department of ACYTER(Advanced Centre for Yoga Thera

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Both genders between 18 and 60 years of age. 2. Newly onset Rheumatoid arthritis patients having disease duration less than 1 year with diagnosis of RA according to the 2010 ACR/EULAR criteria. 3. Rheumatoid arthritis patients partially responding to methotrexate therapy. Details All patients with rheumatoid arthritis (RA) attending the OP or IP services of the Department of Immunology after thorough clinical and laboratory investigations, they will receive methotrexate (unless contraindicated) as initial DMARD (Disease-Modifying Antirheumatic Drugs ) therapy 10 mg per week, escalated @ 5 mg / week, every 2 weeks up to a maximum of 25 mg per week or maximum tolerated dose whichever is less at the end of 6 weeks. Patients will receive NSAlDs (Diclofenac 50 mg twice a day and SOS basis for control of pain). Treatment response will be assessed using EULAR response criteria at the end of three months or after 6 continuous weeks of stable combination DMARD therapy whichever is later. Based on the treatment response patients will be classified as â??good, moderate and poor responderâ??. Patients with complete response to methotrexate will continue the same medication. Whereas, those with poor response will be offered additional DMARD therapy (triple therapy). These two groups will not be recruited in the study. The patients labeled as â??partial respondersâ?? will be continued on methotrexate for a further period of 3 months. They will be enrolled in the study during this phase of stable methotrexate therapy.

Exclusion criteria

Exclusion criteria: 1. Diabetes mellitus 2. Uncontrolled Hypertension (JNC 7 report) 3. Rheumatoid arthritis patients with apparent deformities. 4. Any other neuromuscular disorder. 5. Any other Auto immune disorders. 6. Patients who have undergone yoga therapy or any other bio-feedback techniques in last one year. 7. History of alcoholism or drug abuse within 1 year of screening. 8. Intra-articular steroid injections with in 4 weeks of screening.

Design outcomes

Primary

MeasureTime frame
1.Disease activity scale-28 2.Biochemical & Immunological parameters i) Inflammatory markers 1) ESR 2) IL-6 3) IL-1 4) TNF-α ii) Oxidative stress markers 1) Serum malondialdehyde 2) Total antioxidant status iii) adipokines â?? adiponectin,leptin iv) serum cortisol (8.00 AM) 3. Cardiac autonomic function assessed by short term Heart Rate Variability. 4. BRS(Baroreflex sensitivity) Timepoint: baseline and 12 weeks

Secondary

MeasureTime frame
Quality of life by Health Assessment QuestionnaireTimepoint: baseline and 12 weeks

Countries

India

Contacts

Public ContactG Selvakumar

Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER

drgsgaur@yahoo.com9994470395

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026